OMRF researchers have identified the exact origin point of movement within chromosomes for the first time.
Typically, a promising new experimental drug arrives on the scene with a flourish. But sometimes, it’s a long and winding road.
The findings will allow for more targeted treatment approaches.
In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
If the flu season wrapping up in Australia is any indication, the U.S. may be in for a particularly bad one.
The award-winning Multiple Sclerosis Center of Excellence at OMRF is one of the preeminent MS research and treatment centers in the world.